Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1580
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVIBOL, Iem-
dc.contributor.authorJOHN, S. Bimba-
dc.contributor.authorVICTOR, S. Santos-
dc.contributor.authorJOSE, Dominguez-
dc.contributor.authorJACOB, Creswell-
dc.contributor.authorSILAPHET, Somphavong-
dc.contributor.authorTOM, Wingfield-
dc.contributor.authorJAHANGIR, A. M. Khan-
dc.contributor.authorLUIS, E. Cuevas-
dc.date.accessioned2024-05-31T17:57:44Z-
dc.date.available2024-05-31T17:57:44Z-
dc.date.issued2023-05-22-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/1580-
dc.description.abstractBackground The World Health Organization (WHO) recommends the diagnosis of tuberculosis (TB) using molecular tests, such as Xpert MTB/RIF (MTB/RIF) or Xpert Ultra (Ultra). These tests are expensive and resource-consuming, and cost-effective approaches are needed for greater coverage. Methods We evaluated the cost effectiveness of pooling sputum samples for TB testing by using a fixed amount of 1,000 MTB/RIF or Ultra cartridges. We used the number of people with TB detected as the indicator for cost effectiveness. Cost-minimization analysis was conducted from the healthcare system perspective and included the costs to the healthcare system using pooled and individual testing. Results There was no significant difference in the overall performance of the pooled testing using MTB/RIF or Ultra (sensitivity, 93.9% vs. 97.6%, specificity 98% vs. 97%, p-value>0.1 for both). The mean unit cost across all studies to test one person was 34.10 international dollars for the individual testing and 21.9 international dollars for the pooled testing, resulting in a savings of 12.15 international dollars per test performed (35.6% decrease). The mean unit cost per bacteriologically confirmed TB case was 249.64 international dollars for the individual testing and 162.44 international dollars for the pooled testing (34.9% decrease). Cost-minimization analysis indicates savings are directly associated with the proportion of samples that are positive. If the TB prevalence is ≥30%, pooled testing is not cost-effective. Conclusion Pooled sputum testing can be a cost-effective strategy for diagnosis of TB, resulting in significant resource savings. This approach could increase testing capacity and affordability in resource-limited settings and support increased testing towards achievement of WHO End TB strategy.en_US
dc.language.isoenen_US
dc.publisherBMS INFECTIOUS DISEASESen_US
dc.subjectCOVID-19en_US
dc.subjectTestingen_US
dc.subjectRapid diagnostic testsen_US
dc.subjectSelf-testingen_US
dc.subjectCare pathwaysen_US
dc.subjectCare-seekingen_US
dc.titlePooling sputum testing to diagnose tuberculosis using xpert MTB/RIF and xpert ultra: a cost-effectiveness analysisen_US
dc.typeArticleen_US
Appears in Collections:Research Articles

Files in This Item:
File Description SizeFormat 
s12879-023-08330-9.pdf1.69 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.